v3.20.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents
   September 30,
2020
   December 31,
2019
 
Cash and cash equivalents  $34,364,560   $16,350,237 
Restricted cash   182,892    174,950 
Total cash, cash equivalents and restricted cash  $34,547,452   $16,525,187 

 

Schedule of marketable securities
   Amortized Cost   Gross Unrealized Losses   Gross Unrealized Gains   Fair Value 
September 30, 2020:                
Money Market Funds included in Cash Equivalents  $4,962,810   $
-
   $
-
   $4,962,810 
U.S. Government Agency Securities   
-
    
-
    
-
    
-
 
Corporate Securities   2,375,059    (435)   497    2,375,121 
Commercial Paper   299,636    
-
    13    299,649 
Subtotal   2,674,695    (435)   510    2,674,770 
Total September 30, 2020  $7,637,505   $(435)  $510   $7,637,580 
December 31, 2019:                    
Money Market Funds included in Cash Equivalents  $3,472,043   $
-
   $51   $3,472,094 
U.S. Government Agency Securities   2,691,091    (42)   869    2,691,918 
Corporate Securities   6,058,265    (1,438)   440    6,057,267 
Commercial Paper   3,234,583    (16)   405    3,234,972 
Subtotal   11,983,939    (1,496)   1,714    11,984,157 
Total December 31, 2019  $15,455,982   $(1,496)  $1,765   $15,456,251 

 

Schedule of carrying and fair value of financial assets
   Carrying Value   Level 1   Level 2   Level 3 
September 30, 2020:                
Money Market Funds and Cash Equivalents  $4,962,810   $4,962,810   $
-
   $
      -
 
U.S. Government Agency Securities   -    -    
-
    
-
 
Corporate Securities   2,375,121    
-
    2,375,121    
-
 
Commercial Paper   299,649    
-
    299,649    
-
 
Subtotal   2,674,770    -    2,674,770   $
-
 
Total September 30, 2020  $7,637,580   $4,962,810   $2,674,770   $
-
 
December 31, 2019:                    
Money Market Funds and Cash Equivalents  $3,472,094   $3,472,094   $
-
   $
-
 
U.S. Government Agency Securities   2,691,918    2,691,918    
-
    
-
 
Corporate Securities   6,057,267    
-
    6,057,267    
-
 
Commercial Paper   3,234,972    
-
    3,234,972    
-
 
Subtotal   11,984,157    2,691,918    9,292,239    
-
 
Total December 31, 2019  $15,456,251   $6,164,012   $9,292,239   $
-
 

 

Schedule of other prepaid expenses
   September 30,
2020
   December 31,
2019
 
Deposit on equipment  $500,822   $- 
Insurance   286,241    244,828 
Subscription fees   132,982    97,983 
Software costs   372,454    10,081 
Other   47,740    93,523 
Total  $1,340,239   $446,415 

 

Schedule of inventories
   September 30,
2020
   December 31,
2019
 
Raw materials  $-   $6,893 
Finished goods   351,542    461,735 
Inventory reserve   (150,836)   (130,163)
Total  $200,706   $338,465 

 

Schedule of accrued expenses
   September 30,
2020
   December 31,
2019
 
Professional and consulting fees  $618,472   $214,777 
Accrued payroll and payroll taxes   1,603,245    1,287,047 
Clinical trial related   687    2,435,953 
Manufacturing development related   230,248    806,032 
Other   64,189    54,666 
Total  $2,516,841   $4,798,475 

 

Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share
   Nine Months Ended
September 30,
 
   2020   2019 
   (Number of Shares of Common Stock Issuable) 
Series C-3 non-voting preferred stock   104,000    108,000 
Series E non-voting preferred stock   391,953    391,953 
Series G non-voting preferred stock   5,560,137    5,560,137 
Restricted stock units   
-
    8,411 
Shares issuable for payment of deferred board compensation   45,326    31,498 
Shares underlying outstanding warrants   183,148    344,828 
Shares underlying outstanding stock options   2,427,687    1,435,110 
Total potentially dilutive shares   8,712,251    7,879,937